MRD ve CAR T-Hücre tedavisi arasındaki ilişkileri anlamak
What is MRD in cancer treatment? Measurable Residual Disease, or MRD, is the name for the very few cancer cells that stay in the body after or during treatment. Flow cytometry, polymerase chain reaction (PCR), or next-generati..
Nörolojik bozukluklarda mezenkimal kök hücre tedavisi
Neurological diseases are big problems around the world because they cause a lot of death and disability. Traditional treatments haven't always worked, which has led to a change toward new methods like cell-based therapies. Beca..
Kolorektal kanser tedavisi için FDA tarafından CART T-Hücre Terapisi A2B530'a yetim ilaç adı verildi
In March 2024, a news release said that A2B530 (A2 Biotherapeutics), a CAR T-cell therapy, had been given Orphan Drug Designation to treat colorectal cancer that expresses carcinoembryonic antigen (CEA) and has lost HLA-A*02 expr..
Iovance'ın Amtagvi'si, katı bir tümör için ilk T hücresi tedavisi olarak USFDA tarafından onaylandı
Iovance Biotherapeutics' first-of-its-kind immunotherapy was approved by the FDA. This means that T-cell therapy, which has changed the way some types of blood cancer are treated, can now be used directly on solid tumors.The drug..
Amivantamab-vmjw, EGFR ekson 20 yerleştirme mutasyonlu küçük hücreli olmayan akciğer kanseri endikasyonları için USFDA tarafından onaylandı
The Food and Drug Administration approved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) in combination with carboplatin and pemetrexed on March 1, 2024. Patients with epidermal growth factor receptor (EGFR) exon 20 insertio..
Kemoterapi ile birlikte Osimertinib, EGFR mutasyonlu küçük hücreli dışı akciğer kanseri için USFDA tarafından onaylandı
The Food and Drug Administration approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals LP) in combination with platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (la/mNSC..
Lifileucel, rezeke edilemeyen veya metastatik melanom için USFDA tarafından onaylandı
The Food and Drug Administration granted accelerated approval to lifileucel (Amtagvi, Iovance Biotherapeutics, Inc.) on February 16, 2024. This approval is for adult patients with unresectable or metastatic melanoma who have been..
Tepotinib, metastatik küçük hücreli dışı akciğer kanseri için USFDA tarafından onaylandı
The Food and Drug Administration officially approved tepotinib (Tepmetko, EMD Serono, Inc.) on February 15, 2024, for adult patients with metastatic non-small cell lung cancer (NSCLC) that had mesenchymal-epithelial transition (M..
İrinotekan lipozomu, metastatik pankreas adenokarsinomunun birinci basamak tedavisi için USFDA tarafından onaylandı
The Food and Drug Administration approved irinotecan liposome (Onivyde, Ipsen Biopharmaceuticals, Inc.) with oxaliplatin, fluorouracil, and leucovorin on February 13, 2024, for treating metastatic pancreatic adenocarcinoma as the..
Erdafitinib, lokal ileri veya metastatik ürotelyal karsinom için USFDA tarafından onaylandı
Erdafitinib (Balversa, Janssen Biotech) was approved by the Food and Drug Administration on January 19, 2024, for adult patients with FGFR3 genetic changes who have locally advanced or metastatic urothelial carcinoma (mUC). Patie..